IPSEN (OTCMKTS:IPSEY) Upgraded at Barclays

IPSEN (OTCMKTS:IPSEY) was upgraded by Barclays from a “strong sell” rating to a “hold” rating in a research note issued on Thursday, Zacks reports.

Other equities research analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Finally, Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

IPSEN Price Performance

Shares of IPSEY stock opened at $44.75 on Thursday. IPSEN has a 52 week low of $32.02 and a 52 week high of $51.10. The firm’s 50-day simple moving average is $46.34 and its two-hundred day simple moving average is $46.70.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.